Inventing Disease to Sell Drugs

Selling Diseases



This article is part of Big Pharma, Bad Medicine, a forum on the impact of the pharmaceutical
industry on medical training and science, and the responsibilities ofphysicians.


Marcia Angell notes that industry-funded continuing
medical education (CME) is marketing masquerading as education. I will

focus on this critique because, in fact, CME is the pharmaceutical
industry’s most important marketing tool. Through a largely unnoticed
process that plays out over a course of years, the pharmaceutical
industry uses CME—which, unlike other forms of drug promotion, is not
regulated by the Food and Drug Administration (FDA)—to prepare the
market for new drugs, expand existing markets, position products against
competitors, and promote unproven uses of treatments.

Here’s how it works. Pharmaceutical-company employees, or specialized vendor services, identify opinion leaders—influential (or
up-and-coming) health-care professionals at academic medical centers.
Physicians are the primary target, but as nurse-practitioners and
physician assistants become increasingly important in primary care,
these hidden prescribers are also being targeted. Industry’s influence
on NPs and PAs has not received enough attention; for example, the
recently passed Physician Payments Sunshine Act requires that
pharmaceutical companies disclose payments made to physicians, but not
those made to other prescribers.

Selected opinion leaders are wooed, perhaps over an expensive one-on-one meal with a company researcher or executive—not someone
identified with marketing. In the course of discussing the opinion
leader’s work, the industry representative will elicit his or her
opinions on a variety of topics, including the “disease state” of
interest. Opinion leaders whose perspectives align with a company’s
marketing goals are then courted. A company may nurture relationships
with targeted health-care professionals over many years and will pay
them to educate their peers at CME events and other settings.

Industry-paid speakers frequently deny espousing marketing messages. I’ve heard many physicians justify their pharma-funded
speaking gigs by saying, “I never emphasize their product” or,
triumphantly, “I don’t even mention their drug!” But these comments only
highlight their sales skills. Pharma doesn’t hire doctors to sell
drugs; that’s a drug rep’s job. Pharma hires physicians to sell
diseases.

The process of selling what industry calls a disease state begins many years before a drug is submitted to the FDA for approval. Specific
marketing messages for a product may be developed seven to ten years
before a drug goes on sale. Pre-approval marketing messages assigned to
opinion leaders might emphasize the _under-diagnosis of a targeted
condition, stress the serious consequences of delayed treatment, or
trumpet the importance of a new receptor or novel mechanism of action.

A classic way to expand the market for a drug is to invent a disease state or exaggerate the importance or prevalence of an existing
condition. Here’s a fictitious example of the latter.

The gurgles and rumbles of an empty stomach are called, in medical-speak, borborygmi (it is one of the few onomatopoeic medical
words). Let’s imagine that a company is developing a drug that prevents
borborygmi. The first step would be to encourage people to take the
disease state seriously. Marketing messages developed while the drug is
still undergoing testing might include:

• While the occasional growling stomach is not a cause for concern, regular episodes could indicate the presence of CLASS (Chronic Loud
Atypical Stomach Sounds).

• CLASS is not always benign. The distinction between normal stomach rumbling and a symptom of a serious disease can only be made by a
physician.

• CLASS sufferers may limit their travel, work, and recreational activities out of embarrassment; some may become reclusive, fearing
social stigmatization.

• CLASS can lead to overeating and obesity because sufferers may eat constantly to prevent audible stomach rumbling.

A pharmaceutical company may then begin to recruit physicians to act as mouthpieces for specific marketing messages. A gastroenterologist
may be recruited to explain to prescribers that every person with
stomach rumbling should be examined to rule out a malabsorption disease.
Another physician may be recruited to report that 12 percent of the
population has undiagnosed CLASS, and that some patients have become
homebound because of the condition. A third could announce that CLASS
is a new risk factor for obesity and associated health problems.

Sets of physicians are then invited to medical meetings, including CME events, to educate health-care professionals around the
country about CLASS: it is no laughing matter, but rather a common,
under-diagnosed condition with potentially serious consequences. Because
the disease-state blitz begins years before a product arrives on the
market, audiences are unlikely to connect a drug to the sudden upsurge
of presentations on the disease it is intended to cure.

Although it is illegal for pharmaceutical companies to promote a drug before it is approved, nothing bars pharma-funded physicians from
exaggerating the prevalence, severity, or importance of a disease state
at a CME event in the name of education. By the time the new drug
launches, the disease state is well-established; ideally, CLASS is
accepted as a reimbursable diagnosis, and medical students are taught to
treat what once was known to be a harmless manifestation of normal
gastrointestinal function.

Other companies that want a piece of the CLASS market may create me-too drugs, and then hire opinion leaders to differentiate their new
products from existing ones. When more than one treatment is available,
opinion leaders might be assigned to highlight the deficiencies of
competitive therapies; compare mechanisms of action (only drug X
suppresses CLASS-associated disordered gastric rhythms); or invent
diagnostic distinctions by, for example, dividing borborygmi into two
subtypes, one of which is tailor-made for a new drug.

Opinion leaders are supported by industry only as long as what they say advances marketing goals. A prescriber who expresses doubts
about an assigned product’s efficacy, concerns about its risks, or
enthusiasm for a nonmarketable lifestyle change (say, exercise) as a
superior therapy, will be dropped from a company’s speakers list.

Industry-paid speakers are pushing a product, even if they don’t realize it, and health-care professionals at industry-funded CME events
are listening to marketing messages, even if they, too, are oblivious
to this fact. As Angell points out, by paying for CME and other forms of
“education,” companies are simply buying access to prescribers.
Lawyers, accountants, and other professionals pay for their continuing
education. It is time for doctors, nurses, and physician assistants to
pick up their own tab.

http://bostonreview.net/BR35.3/fugh-berman.php

Views: 125

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

Comment by Nikki on May 13, 2010 at 12:33pm
And they trick doctors by calling it "continuing medical education." In many fields of medicine doctors knew more 50 years ago than they do today. And that's because Big Pharma has too much influence over what is taught in medical school.
Comment by Tara on May 13, 2010 at 10:27am
Great post Nikki! You know what I think......while they are concocting all these new diseases, it is only right for them to test the drugs out on themselves first. I'm sure there is a diseased few in their midst. These corrupt doctors and pharma ho's are so good at making up new diseases, I believe they need a dose of their own medicine, literally!
Comment by Harry Thomas on May 13, 2010 at 1:36am
problem , reaction , solution

They want to sell drugs and (implement eugenics) , They create diseases in labs (also eugenics) , They sell the solution (drugs, ideas) to the public .
Simple and very effective

"Destroying the New World Order"

TOP CONTENT THIS WEEK

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

Latest Activity

Sandy posted a photo
11 minutes ago
Doc Vega posted a blog post
10 hours ago
Saint Quinn favorited Burbia's video
yesterday
Doc Vega posted blog posts
yesterday
Burbia commented on tjdavis's blog post The Jewish Couple That Taught Bob Dylan Hebrew and Introduced Him to Zionism
"Haaretz put this story behind a pay wall. Sali Ariel and Terry Noble were the names of the couple…"
Wednesday
William Heckman is now a member of 12160 Social Network
Wednesday
cheeki kea commented on tjdavis's photo
Wednesday
cheeki kea commented on cheeki kea's video
Thumbnail

This Woman DESTROYED Harley-Davidson's Future Forever

"It's a sad day on the highway. But I guess the show must go on. Watch out for the ruination of…"
Wednesday
cheeki kea posted a video

This Woman DESTROYED Harley-Davidson's Future Forever

This Woman DESTROYED Harley-Davidson's Future ForeverWelcome to Ride Radar – Your Frontline Source for Motorcycle Deals, Trends & Market Mayhem.Looking for t...
Wednesday
tjdavis posted a photo
Wednesday
Burbia posted a status
"Who knew releasing the MLK files and literally deflecting, it ends up implicating himself with the Epstein Files."
Tuesday
Burbia posted a video

Dan Bilzerian DEMOLISHES MAGA Nutjob Patrick Bet-David on His Own Show

Watch as two powerhouse personalities collide in this no-holds-barred debate on one of the world’s most contentious issues. Patrick Bet-David, known for his ...
Monday
Doc Vega's 7 blog posts were featured
Sunday
tjdavis's 2 blog posts were featured
Sunday
Less Prone favorited tjdavis's blog post Track AIPAC
Sunday
FREEDOMROX's blog post was featured

MRNA VACCINES: Question

Hello my fellow sojourners,I know it has been five years since the Plandemic, but one question has…See More
Sunday
Less Prone favorited FREEDOMROX's blog post MRNA VACCINES: Question
Sunday
cheeki kea commented on cheeki kea's photo
Jul 19
cheeki kea posted a photo
Jul 19
Doc Vega posted blog posts
Jul 18

© 2025   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted